The . Pharmacopoeial Convention has concluded that rituximab is indicated for treatment of Waldenström’s macroglobulinemia. Dimopolous et al (2002) reported on 27 patients with symptomatic Waldenström’s macroglobulinemia who were treated with rituximab. Twelve patients (44 %; 95 % confidence interval [CI]: % to %) achieved a partial response after treatment with rituximab. Median time to response was months (range of to months). The median time to progression for all patients was 16 months, and with a median follow-up of months, 9 of 12 responding patients remain free of progression. The investigators reported that approximately 25 % of patients experienced some mild form of infusion-related toxicity, usually fever and chills.